Annual Report
2023
Menu
Search
Annual Report
2023
Menu
Main menu
argenx Group
argenx Group
Shareholder Letter
2023 In Brief
2024 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
Empasiprubart Development
ARGX-119 Development
ARGX-109, ARGX-220, ARGX-121 and ARGX-213 Development
Immunology Innovation Program
Collaborations and Licenses
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Documents on display
Risk Factors
Risk Factors
Summary
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
American Depository Shares
Being a Foreign Private Issuer or a Dutch Company
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Say-on-pay and proposed Amendments to the Remuneration Policy
2023 Remuneration
Named Executive Officer Remuneration
Remuneration of Other Senior Management Members
Non-Executive Remuneration
Pay Ratios
Other Disclosures
Corporate Governance
Share Ownership
Insider Trading
Cybersecurity
Risk Appetite & Control
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
Limitations on the right to hold securities
General Meeting, Voting Rights and Admission
Anti-Takeover Provisions
Exchange Controls
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Right to a surplus in the event of a liquidation
Material Modifications to the Rights of Security Holders and Use of Proceeds
Enforcement of civil liabilities
Controls and Procedures
Financial Calendar 2024
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Research and Development, Patents and Licenses
Trend Information
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Insurance
Legal and Arbitration Proceedings
Taxation
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income (Loss)
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Material Accounting Policy Information
3.
Critical Accounting Estimates and Judgments
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Other Non-Current Assets
7.
Inventories
8.
Prepaid Expenses (Current)
9.
Trade and Other Receivables
10.
Financial Assets – Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/(Losses)
24.
Income taxes
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Patient Stories
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
argenx Group
argenx Group
Shareholder Letter
2023 In Brief
2024 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
Empasiprubart Development
ARGX-119 Development
ARGX-109, ARGX-220, ARGX-121 and ARGX-213 Development
Immunology Innovation Program
Collaborations and Licenses
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Documents on display
Risk Factors
Risk Factors
Summary
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
American Depository Shares
Being a Foreign Private Issuer or a Dutch Company
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Say-on-pay and proposed Amendments to the Remuneration Policy
2023 Remuneration
Named Executive Officer Remuneration
Remuneration of Other Senior Management Members
Non-Executive Remuneration
Pay Ratios
Other Disclosures
Corporate Governance
Share Ownership
Insider Trading
Cybersecurity
Risk Appetite & Control
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
Limitations on the right to hold securities
General Meeting, Voting Rights and Admission
Anti-Takeover Provisions
Exchange Controls
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Right to a surplus in the event of a liquidation
Material Modifications to the Rights of Security Holders and Use of Proceeds
Enforcement of civil liabilities
Controls and Procedures
Financial Calendar 2024
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Research and Development, Patents and Licenses
Trend Information
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Insurance
Legal and Arbitration Proceedings
Taxation
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income (Loss)
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Material Accounting Policy Information
3.
Critical Accounting Estimates and Judgments
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Other Non-Current Assets
7.
Inventories
8.
Prepaid Expenses (Current)
9.
Trade and Other Receivables
10.
Financial Assets – Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/(Losses)
24.
Income taxes
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Patient Stories
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
argenx Group
argenx Group
Shareholder Letter
2023 In Brief
2024 Outlook
Company Profile
Strategy and Objectives
Our Products and Product Candidates
Our Products and Product Candidates
VYVGART
Efgartigimod Development
Efgartigimod Indications
Empasiprubart Development
ARGX-119 Development
ARGX-109, ARGX-220, ARGX-121 and ARGX-213 Development
Immunology Innovation Program
Collaborations and Licenses
Distribution Agreements
Manufacturing and Supply
Intellectual Property
Regulation
Regulation
Licensure and Regulation of Biologics in the U.S.
Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK
Regulation and Procedures Governing Approval of Medicinal Products in Japan
Coverage, Pricing and Reimbursement
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Healthcare Law and Regulation
Healthcare Reform
Environmental Issues which may Influence the Use of our Material Fixed Assets
Documents on display
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Risk Factors
Risk Factors
Summary
Financial Position and Additional Capital
Commercialization
Other Government Regulations
Development and Clinical Testing
Dependence on Third Parties
Business and Industry
Intellectual Property
Organization and Operations
American Depository Shares
Being a Foreign Private Issuer or a Dutch Company
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Corporate Governance
Corporate Governance
Dutch Corporate Governance Code
Management Structure
Management Structure
General
Statement of the Board of Directors
Board of Directors
Non-Executive Directors
Senior Management
Conflict-of-Interest Transactions
Code of Business Conduct and Ethics
Report of the Non-Executive Directors
Remuneration Report
Remuneration Report
Say-on-pay and proposed Amendments to the Remuneration Policy
2023 Remuneration
Named Executive Officer Remuneration
Remuneration of Other Senior Management Members
Non-Executive Remuneration
Pay Ratios
Other Disclosures
Corporate Governance
Share Ownership
Insider Trading
Cybersecurity
Risk Appetite & Control
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Share Capital
Share Capital
Legal Information on the Company
Share Capital
Share Classes and Principal Shareholders
Limitations on the right to hold securities
General Meeting, Voting Rights and Admission
Anti-Takeover Provisions
Exchange Controls
Amendments of Articles of Association
Transparency Directive
Dutch Financial Reporting Supervision Act
Dividends and Other Distributions
Right to a surplus in the event of a liquidation
Material Modifications to the Rights of Security Holders and Use of Proceeds
Enforcement of civil liabilities
Controls and Procedures
Financial Calendar 2024
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Financial Review
Financial Review
Overview
Basis of Presentation
Capitalization and Indebtedness
Critical Accounting Estimates and Judgments
Results of Operation
Liquidity and Capital Resources
Research and Development, Patents and Licenses
Trend Information
Off-Balance Sheet Arrangements
Contractual Obligations
Information Regarding the Independent Auditor
Material Contracts and Related Party Transactions
Employees
Insurance
Legal and Arbitration Proceedings
Taxation
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Financial Statements
Financial Statements
Consolidated Financial Statements
Consolidated Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Profit or Loss
Consolidated Statements of Comprehensive Income (Loss)
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes to the Consolidated Financial Statements
1.
General Information about the Company
2.
Material Accounting Policy Information
3.
Critical Accounting Estimates and Judgments
4.
Property, Plant and Equipment
5.
Intangible Assets
6.
Other Non-Current Assets
7.
Inventories
8.
Prepaid Expenses (Current)
9.
Trade and Other Receivables
10.
Financial Assets – Current
11.
Cash and Cash Equivalents
12.
Share Capital and Share Premium
13.
Share-Based Payments
14.
Trade and Other Payables
15.
Product Net Sales
16.
Collaboration Revenue
17.
Other Operating Income
18.
Segment Reporting
19.
Research and Development Expenses
20.
Selling, General and Administrative Expenses
21.
Personnel Expenses
22.
Leases
23.
Financial Result and Exchange Gains/(Losses)
24.
Income taxes
25.
Loss per Share
26.
Financial Risk Management
27.
Related Party Transactions
28.
Contingencies
29.
Commitments
30.
Audit Fees
31.
Overview of Consolidation Scope
32.
Events After the Balance Sheet Date
Company Financial Statements
Company Financial Statements
Signatures of Executive and Non-Executive Directors
Company Financial Statements for argenx SE
Notes to the Company Financial Statements
Other Information
Independent Auditor’s Report
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Non-Financial Information
Non-Financial Information
Regulations and Compliance
NFRD
EU Taxonomy
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Patient Stories
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Glossary
Glossary
Cross Reference table for annual reporting requirement
Management Confirmations
Definitions
Quick links
Patient Stories
Year 2023 in Brief
Outlook for Year 2024
Download center
Home
Search
Search
Downloads
Facebook
Twitter
LinkedIn
E-Mail
